Sensus Healthcare, Inc. (NASDAQ:SRTS) had its price target hoisted by Maxim Group from $6.50 to $7.50 in a research report issued on Friday. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective suggests a potential upside of 27.33% from the company’s current price.

Shares of Sensus Healthcare (NASDAQ SRTS) traded up $0.04 during midday trading on Friday, reaching $5.89. 10,864 shares of the company were exchanged, compared to its average volume of 15,661.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, August 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.08. Sensus Healthcare had a negative net margin of 17.21% and a negative return on equity of 23.48%. The firm had revenue of $4.97 million for the quarter, compared to analyst estimates of $4.50 million. research analysts forecast that Sensus Healthcare will post -0.33 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Sensus Healthcare, Inc. (SRTS) PT Raised to $7.50” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/05/sensus-healthcare-inc-srts-pt-raised-to-7-50.html.

In related news, insider Kalman Fishman sold 5,378 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $6.00, for a total transaction of $32,268.00. Following the sale, the insider now owns 990,845 shares in the company, valued at $5,945,070. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Joseph C. Sardano sold 6,953 shares of the firm’s stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $6.00, for a total transaction of $41,718.00. Following the sale, the chief executive officer now owns 1,587,701 shares in the company, valued at approximately $9,526,206. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 98,551 shares of company stock worth $591,306. 41.70% of the stock is owned by company insiders.

A hedge fund recently bought a new stake in Sensus Healthcare stock. B. Riley Financial Inc. purchased a new position in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 104,794 shares of the company’s stock, valued at approximately $421,000. B. Riley Financial Inc. owned 0.77% of Sensus Healthcare as of its most recent SEC filing. 8.09% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, formerly Sensus Healthcare, LLC, is a manufacturer of superficial radiation therapy devices. The Company designs, manufactures and markets medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy.

Receive News & Ratings for Sensus Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.